 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Cardiovascular Pharmacology Fellow, School of Pharmacy, University of Connecticut; Divisions of Cardiology and Drug Information, Hartford Hospital, Hartford, CT
Associate Professor, School of Pharmacy, University of Connecticut; Director, Cardiac Pharmacology Service, Divisions of Cardiology and Drug Information, Hartford Hospital
Reprints: Dr. White, Hartford Hospital, 80 Seymour St., Hartford, CT 06102, fax 860/545-2277, cmwhite{at}harthosp.org
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of dronedarone for the treatment of atrial fibrillation.
DATA SOURCES: A literature search was conducted using the search terms dronedarone, SR 33589, atrial fibrillation, and antiarrhythmic medication in MEDLINE (1966–February 2007), International Pharmaceutical Abstracts (1970–February 2007), and EMBASE (1990–February 2007). References from the identified trials and selected review articles were evaluated. Additional information, including abstracts and posters, was obtained from Sanofi-Aventis.
STUDY SELECTION AND DATA EXTRACTION: Published studies and meeting abstracts evaluating the effects of dronedarone in humans and animals were reviewed.
DATA SYNTHESIS: Dronedarone is a novel antiarrhythmic medication to treat atrial fibrillation. Dronedarone has a multifaceted mechanism of action similar to that of amiodarone. Dronedarone works by blocking potassium, sodium, and calcium channels and exhibits antiadrenergic properties. The drug has been evaluated at doses of 400, 600, and 800 mg twice daily. It prolonged the time to atrial fibrillation recurrence to 60–158 days compared with 5–59 days with placebo and decreased heart rate during atrial fibrillation by 12–25 beats/min in clinical trials. Major adverse events include gastrointestinal side effects and risk of proarrhythmia. Dronedarone may increase the risk of mortality in patients with congestive heart failure.
CONCLUSIONS: Dronedarone is a new antiarrhythmic agent for the treatment of atrial fibrillation. Further studies are needed to better define dronedarone's safety profile and place in therapy.
Key Words: atrial fibrillation, atrial flutter, dronedarone
Published Online, March 27, 2007. www.theannals.com, DOI 10.1345/aph.1H524
This article has been cited by other articles:
|
|
 |
|
  R. H. Falk and A. J. Camm Rethinking the reasons to treat atrial fibrillation? The role of dronedarone in reducing cardiovascular hospitalizations Eur. Heart J., October 2, 2009; 30(20): 2438 - 2440. [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Mason and J. P. DiMarco New Pharmacological Agents for Arrhythmias Circ Arrhythm Electrophysiol, October 1, 2009; 2(5): 588 - 597. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Piccini, V. Hasselblad, E. D. Peterson, J. B. Washam, R. M. Califf, and D. F. Kong Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J. Am. Coll. Cardiol., September 15, 2009; 54(12): 1089 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Crandall, D. J. Bradley, D. L. Packer, and S. J. Asirvatham Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies Mayo Clin. Proc., July 1, 2009; 84(7): 643 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Khoo and G. Y. H. Lip Acute Management of Atrial Fibrillation Chest, March 1, 2009; 135(3): 849 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Camm and J. A. Reiffel Defining endpoints in clinical trials on atrial fibrillation Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H55 - H78. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
